97 related articles for article (PubMed ID: 1784409)
1. [Fibrinogen and factor VII levels in patients under estrogen-progestin therapy].
Tani M; Bossini S; Maffetti G
Minerva Ginecol; 1991 Nov; 43(11):519-24. PubMed ID: 1784409
[TBL] [Abstract][Full Text] [Related]
2. [Fibrinogen and factor VII in women with dyslipidemia. The preliminary results of the Bellvitge-Costa de Ponent Study. The Bellvitge Study Group].
Val A; Espínola A; Domenech P; Argimón JM; Castells A; Pintó X; Fiol C
Med Clin (Barc); 1995 Jul; 105(5):161-3. PubMed ID: 7630226
[TBL] [Abstract][Full Text] [Related]
3. Changes in haemostatic variables induced by oral contraceptives containing 50 micrograms or 30 micrograms oestrogen: absence of dose-dependent effect on PAI-1 activity.
Scarabin PY; Plu-Bureau G; Zitoun D; Bara L; Guize L; Samama MM
Thromb Haemost; 1995 Sep; 74(3):928-32. PubMed ID: 8571323
[TBL] [Abstract][Full Text] [Related]
4. Associations of fibrinogen, factor VII and PAI-1 with baseline findings among 10,500 male participants in a prospective study of myocardial infarction--the PRIME Study. Prospective Epidemiological Study of Myocardial Infarction.
Scarabin PY; Aillaud MF; Amouyel P; Evans A; Luc G; Ferrières J; Arveiler D; Juhan-Vague I
Thromb Haemost; 1998 Nov; 80(5):749-56. PubMed ID: 9843166
[TBL] [Abstract][Full Text] [Related]
5. Altered blood coagulation in patients with posttraumatic stress disorder.
von Känel R; Hepp U; Buddeberg C; Keel M; Mica L; Aschbacher K; Schnyder U
Psychosom Med; 2006; 68(4):598-604. PubMed ID: 16868270
[TBL] [Abstract][Full Text] [Related]
6. [Factor VII and cardiovascular risk in obese subjects].
Craveri A; Tornaghi G; Ranieri R; Paganardi L; Torti P; Marelli F; Moroni GA
Ann Ital Med Int; 1990; 5(2):118-20. PubMed ID: 2248859
[TBL] [Abstract][Full Text] [Related]
7. [Cardiovascular risks of oral contraceptives: dose-response relationship].
Kelleher CC
Contracept Fertil Sex (Paris); 1991 Apr; 19(4):285-8. PubMed ID: 12343220
[TBL] [Abstract][Full Text] [Related]
8. The adverse effects of hormonal therapy.
Bush TL
Cardiol Clin; 1986 Feb; 4(1):145-52. PubMed ID: 3518931
[TBL] [Abstract][Full Text] [Related]
9. Circulatory effects of estrogen.
Kushner S
Ohio State Med J; 1970 Oct; 66(10):1016-21. PubMed ID: 4918754
[No Abstract] [Full Text] [Related]
10. [Factor VII and protein-C markers are no prognostic indicators in acute coronary heart disease].
Friesewinkel O; Marbet GA; Ritz R
Schweiz Med Wochenschr; 1993 Jan; 123(3):82-4. PubMed ID: 8426952
[TBL] [Abstract][Full Text] [Related]
11. Blood coagulation, fibrinolytic activity and lipid profile in subclinical thyroid disease: subclinical hyperthyroidism increases plasma factor X activity.
Erem C
Clin Endocrinol (Oxf); 2006 Mar; 64(3):323-9. PubMed ID: 16487444
[TBL] [Abstract][Full Text] [Related]
12. Tibolone, transdermal estradiol or oral estrogen-progestin therapies: effects on circulating allopregnanolone, cortisol and dehydroepiandrosterone levels.
Pluchino N; Genazzani AD; Bernardi F; Casarosa E; Pieri M; Palumbo M; Picciarelli G; Gabbanini M; Luisi M; Genazzani AR
Gynecol Endocrinol; 2005 Mar; 20(3):144-9. PubMed ID: 16019353
[TBL] [Abstract][Full Text] [Related]
13. The predictive value of admission and follow up factor V and VII levels in patients with acute hepatitis and coagulopathy.
Elinav E; Ben-Dov I; Hai-Am E; Ackerman Z; Ofran Y
J Hepatol; 2005 Jan; 42(1):82-6. PubMed ID: 15629511
[TBL] [Abstract][Full Text] [Related]
14. [Recent advances in the study of blood coagulation].
Yamanaka M
Rinsho Byori; 1971 Feb; 19(2):111-8. PubMed ID: 4939390
[No Abstract] [Full Text] [Related]
15. Estrogen, progestogens and cardiovascular risk.
Stefanick ML
J Reprod Med; 1999 Feb; 44(2 Suppl):221-6. PubMed ID: 11392036
[TBL] [Abstract][Full Text] [Related]
16. Hemostatic variables in the prediction of coronary risk: results of the 8 year follow-up of healthy men in the Münster Heart Study (PROCAM). Prospective Cardiovascular Münster Study.
Assmann G; Cullen P; Heinrich J; Schulte H
Isr J Med Sci; 1996 Jun; 32(6):364-70. PubMed ID: 8682642
[TBL] [Abstract][Full Text] [Related]
17. KEEPS: The Kronos Early Estrogen Prevention Study.
Harman SM; Brinton EA; Cedars M; Lobo R; Manson JE; Merriam GR; Miller VM; Naftolin F; Santoro N
Climacteric; 2005 Mar; 8(1):3-12. PubMed ID: 15804727
[TBL] [Abstract][Full Text] [Related]
18. Comparative cardiovascular effects of different progestins in menopause.
Rosano GM; Fini M
Int J Fertil Womens Med; 2001; 46(5):248-56. PubMed ID: 11720197
[TBL] [Abstract][Full Text] [Related]
19. [Congenital and familial dysfibrinogenemia without hemorrhagic tendancy].
Samama M; Soria J; Soria C; Bousser J
Nouv Rev Fr Hematol; 1969; 9(6):817-32. PubMed ID: 4245042
[No Abstract] [Full Text] [Related]
20. Increased levels of activated factor VII and decreased plasma protein S activity and circulating thrombomodulin during use of oral contraceptives.
Quehenberger P; Loner U; Kapiotis S; Handler S; Schneider B; Huber J; Speiser W
Thromb Haemost; 1996 Nov; 76(5):729-34. PubMed ID: 8950781
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
